Description: Intelligent Bio Solutions, Inc. (Nasdaq: INBS) is a New York–headquartered medical-technology company commercializing a non-invasive fingerprint sweat drug-screening platform — a portable handheld reader paired with single-use cartridges that returns results in under ten minutes. The company reports 480-plus active customer accounts across 27 countries and more than 1,700 installed readers. Fiscal first-half 2026 revenue was $2.01 million, up 36% year over year, with gross margins expanding to 49% from 39%. Two facts coexist. On one side, operating momentum is genuinely improving: reader sales doubled year over year in the second quarter, customer additions accelerated, and a manufacturing partnership with Syrma Johari is projected to deliver greater than 40% annual production cost savings. On the other, the company executed a 1-for-10 reverse stock split in December 2025 to address a Nasdaq minimum-bid-price deficiency — and is operating under an initial 180-day compliance window that expires June 15, 2026. The FDA 510(k) clearance pathway that would unlock U.S. market entry is in motion but is not under the company's direct timing control.
Category: Finance
Tag: Smallcap stock news